US 12,441,812 B2
Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules
Maria Amann, Duebendorf (CH); Peter Bruenker, Hittnau (CH); Christina Claus, Ennetbaden (CH); Claudia Ferrara Koller, Zug (CH); Sandra Grau-Richards, Birmensdorf (CH); Christian Klein, Bonstetten (CH); Viktor Levitski, Schlieren (CH); Ekkehard Moessner, Kreuzlingen (CH); Joerg Thomas Regula, Munich (DE); and Pablo Umana, Wollerau (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Jan. 21, 2022, as Appl. No. 17/580,980.
Application 17/580,980 is a division of application No. 16/522,412, filed on Jul. 25, 2019, granted, now 11,267,903.
Application 16/522,412 is a division of application No. 15/067,024, filed on Mar. 10, 2016, granted, now 10,392,445, issued on Aug. 27, 2019.
Application 15/067,024 is a continuation of application No. PCT/EP2015/076528, filed on Nov. 13, 2015.
Claims priority of application No. 14193260 (EP), filed on Nov. 14, 2014; application No. 15183736 (EP), filed on Sep. 3, 2015; and application No. 15188142 (EP), filed on Oct. 2, 2015.
Prior Publication US 2022/0259327 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 39/395 (2013.01); C07K 14/70575 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2815 (2013.01); C07K 16/2896 (2013.01); C07K 16/3007 (2013.01); A61K 38/00 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 28 Claims
 
1. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises:
(a) at least one antigen-binding domain comprising an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH) capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and
(b) a first polypeptide and a second polypeptide that are linked to each other by a disulfide bond, wherein the first polypeptide comprises two ectodomains of a TNF family ligand or fragments thereof that are connected to each other by a peptide linker and the second polypeptide comprises only one ectodomain of the TNF family ligand or fragment thereof,
wherein the TNF family ligand is 4-1BBL.